In contrast to inhibition of MCT1, 3‐OBA decreased the anti‐myeloma effect of BTZ (of about 5.4 ± 2.7% compared to BTZ‐treated cells; p < 0.01; Figure 2C) but not of CFZ (Figure 2F). This evidence concerns the gene SLC16A1 and plasma cell myeloma.